Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes
necessary for their growth.
PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating
patients with HIV-related Kaposi's sarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
National Cancer Institute (NCI) The Emmes Company, LLC The EMMES Corporation